David Burns appointed CEO/President of Cellectricon
Cellectricon appoints David Burns as the company's Chief Executive Officer. David brings a solid and highly impressive international Life Science executive track record to Cellectricon.
Cellectricon is a life sciences solutions provider of advanced cell based assay technology. The company’s proprietary technologies solve critical bottlenecks in drug discovery & cell based research
| Any ion channel target | Any cell type | Unrivalled assay flexibility |
Covers all your screening needs for both ligand- and voltage-gated ion channels! Highest throughput of any dose-response screening system on the market.
| Any receptor & cell type | Safety pharmacology | Neuroscience |
Dynaflow®Pro II turns your existing patch clamp rig into a flexible electrophysiology system compatible with any cell type, any receptor and any patch clamp configuration.
Expand your research from cell lines to primary cells. Neuronal tissue slices and primary neuronal cultures can finally be efficiently transfected with excellent viability!
“We have now a new electroporation
procedure using the Cellaxess® system
for hard-to-transfect neurons. Our
obtained result on transient transfection
of adherent primary neurons is published
in: J Neurosci Methods. 2010”
------------------------------------------
Dr. Lena Scott, Karolinska Institute
“Thanks to the unique features of the
Cellaxess® system we are very pleased
to have incorporated the technology into
our research. Cellaxess® enables
electroporation of hard-to-transfect cells
and the results we obtained on striatum
slice cultures were published in
Neuroscience, 2009”
------------------------------------------
Dr. Catia Andreassi, MRC LMCB,
University College London
“The Cellaxess® technology enabled us
to perform high-efficiency transfection of
plasmid DNA and siRNAs in primary
sympathetic neurons. The results
obtained were published in Nature
Neuroscience 2010.”
------------------------------------------
Dr. Anders B. Eriksson, AstraZeneca
“The collaboration between AstraZeneca and Cellectricon aims to accelerate our efforts in ion channel drug discovery and has been fruitful to date. The Dynaflow®HT System addresses the limits of existing ion channel screening equipment by combining automated throughput with accurate and affordable data measurement.”
------------------------------------------
Dr. Andrew Southan, BioFocus DPI
“The Dynaflow®HT system provides
opportunities to configure assays against
both voltage-gated and ligand-gated ion
channels, with the microfluidic perfusion
system offering a unique advantage for
ligand-gated ion channel research. In
our experience the system offers
extremely cost-efficient high throughput
experiments without the need for
user intervention.”
------------------------------------------
Wyeth Research & Sienna Biotech SpA
“To measure the fast activation and
desensitization of alpha-7 current during
the electrophysiology experiments, two
Dynaflow®Pro II systems were used.”
The results obtained were published in
J. Med. Chem., 2010.
------------------------------------------
Dr Luidmila Polonchuk
F. Hoffman – La Roche Ltd.
”The Dynaflow®TC System greatly
facilitates the handling of our safety
pharmacology drug screening. It gives us
higher success rate in seal formation and
increases stability of recordings. We are very
pleased to have incorporated the system
since it increases the throughput as well as
minimizes the amount of compounds used”.
